ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Atrial Fibrillation Clinical Trial

Official title:

Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04467905
• Other study ID #: MSP-2017-5001
• Status: Completed
• Phase: Phase 2
• Start date: November 19, 2020
• Est. completion date: August 10, 2023

Study information

• Verified date: October 2023
• Source: Milestone Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Many patients with atrial fibrillation experience persistent tachycardia with episodes of rapid ventricular rate despite chronic treatment to reduce ventricular rate. The objectives of this study are to demonstrate the superiority of a nasal spray of etripamil over placebo, in reducing ventricular rate in patients with atrial fibrillation; and to evaluate the safety and efficacy of etripamil Nasal Spray in patients with atrial fibrillation (AF).

Description:

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil Nasal Spray in patients with atrial fibrillation (AF). This study includes Screening, the Treatment Period (Screening and Treament Period occur on the same day) and Follow-up procedures.

Each patient will receive placebo or 70 mg of etripamil intranasally; treatment will be randomized in a 1:1 ratio, to yield 50 evaluable patients with atrial fibrillation in 2 groups of 25.

Patients with atrial fibrillation (AF) will be selected by the Investigator. The screening procedures will include obtaining informed consent, a review of inclusion/exclusion criteria, a complete physical examination, and recording of any concomitant medications.

After screening procedures are complete, eligible patients will be randomized to receive etripamil or placebo. Heart rate will be measured via Holter ECG (Electrocardiogram)10 minutes prior to and immediately before drug administration; patients must exhibit a rapid ventricular rate (≥110 bpm measured during 1 minute) on the Holter report prior to drug administration in order to receive the study drug. Blinded study drug will be administered during Holter ECG (Electrocardiogram) monitoring, which will be conducted for at least 10 minutes prior to and for 6 hours after administration, patient discharged after 60 minutes if clinically warranted.

Patients will undergo a safety follow-up assessment and return the Holter device approximately 24 hours post-dose. Patients will also be contacted by phone 7 days post-dosing for safety follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: August 10, 2023
• Est. primary completion date: August 3, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

A patient will be eligible for study participation if they meet all of the following criteria:

1. Aged 18 years and over.

2. Has provided written informed consent.

3. Patients with episodes of paroxysmal, persistent or permanent AF (Atrial Fibrillation), presenting with AF and a ventricular rate =110 bpm, measured over 1 minute

4. Patients should receive appropriate antithrombotic therapy as per the applicable guidelines for atrial fibrillation management (e.g., Canadian Cardiovascular Society (CCS) guidelines / European Society of Cardiology (ESC) guidelines).

1. Etripamil (a calcium channel blocker) is intended for acute rate control only. If rhythm control is desired (outside of the present protocol), anticoagulation as per guidelines may start after the administration of study drug.

Exclusion Criteria:

A patient will be excluded from the study if they meet any of the following criteria:

1. Has evidence of atrial flutter (ECG) at presentation.

2. Has a history of stroke,Transient Ischemic Attack (TIA) or peripheral embolism within the last 3 months.

3. Has received by IV route any of the following within one hour before study drug administration: flecainide, procainamide, digoxin, beta-blocker, or calcium channel blocker.

4. Has signs and symptoms of severe congestive heart failure at presentation (e.g. tachypnea, oxygen desaturation <90% unless due to known pulmonary disease, pulmonary rales, sign of peripheral hypoperfusion).

5. Hemodynamic instability, with systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg.

6. Known uncorrected severe aortic or mitral stenosis.

7. Hypertrophic cardiomyopathy with outflow tract obstruction.

8. Has a history of second- or third-degree atrioventricular block.

9. Regular rhythm suggesting a complete Atrioventricular (AV) block.

10. Has a history or evidence of torsades de pointes, sick sinus syndrome, or Brugada syndrome.

11. Evidence of Acute Coronary Syndrome within the last 12 months except if patient was successfully revascularized.

12. Positive pregnancy test result at screening, and females of childbearing potential who do not agree to use adequate method of contraception for the duration of the study.

13. Has evidence of any clinically significant acute or chronic condition of the nasal cavity (e.g., rhinitis or deviated septum) which could interfere with administration of the study drug in either or both nasal cavities.

14. Has a history of sensitivity to verapamil.

15. Has previously participated in a clinical study for etripamil.

16. Has a history of sensitivity to any components of the investigational product.

17. Signs of alcohol or drug intoxication at the time of presentation which, in the opinion of the Investigator, would impact the validity of study results.

18. Is currently participating in another drug or device study, or has received an investigational drug or device within 30 days of Screening.

19. Has evidence of clinically significant cardiovascular, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, pulmonary, psychiatric, or renal disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the patient or impact the validity of study results.

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• Etripamil
The formulation of etripamil Nasal Spray will consist of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
• Placebo
The formulation of placebo will consist of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.

Locations

Country	Name	City	State
Canada	QEII HSC - Nova Scotia Health Authority	Halifax	Nova Scotia
Canada	Hamilton Health Science	Hamilton	Ontario
Canada	CHU Montréal	Montréal	Quebec
Canada	CIUSSS du Nord-de-l'Île-de-Montréal - Hôpital du Sacré-Cœur	Montréal	Quebec
Canada	Institut de Cardiologie de Montreal	Montréal	Quebec
Canada	PACE (Partners in Advanced Cardiac Evaluation)	Newmarket	Ontario
Canada	Ottawa Hospital General & Civic Campus Research Institute	Ottawa	Ontario
Canada	CISSS Bas-Saint-Laurent / Hôpital de Rimouski	Rimouski	Quebec
Canada	CISSS des Laurentides / Unité de recherche clinique	Saint-Jérôme	Quebec
Canada	CIUSSS de l'Estrie - CHU	Sherbrooke	Quebec
Canada	CISSS de Lanaudière - Hôpital Pierre-Le Gardeur	Terrebonne	Quebec
Netherlands	Jeroen Bosch Ziekenhuis Rijnstate Ziekenhuis	Arnhem
Netherlands	Jeroen Bosch Ziekenhuis	Den Bosch
Netherlands	Slingeland Ziekenhuis	Doetinchem
Netherlands	Treant Zorggroep	Emmen
Netherlands	Elkerliek Ziekenhuis	Helmond
Netherlands	Franciscus Gasthuis	Rotterdam
Netherlands	Gelre Ziekenhuizen	Zutphen

Sponsors (3)

Lead Sponsor	Collaborator
Milestone Pharmaceuticals Inc.	JSS Medical Research Inc., The Montreal Health Innovations Coordinating Center (MHICC)

Countries where clinical trial is conducted

Canada,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum reduction in ventricular rate, measured on Holter monitoring, within 60 minutes from drug administration.		60 minutes post drug administration
Secondary	The elapsed time from drug administration to nadir (lowest average heart rate) in the 60 minutes post drug administration.		60 minutes post drug administration
Secondary	The percentage of patients achieving ventricular rate of <100 bpm in the 60 minutes post drug administration.		60 minutes post drug administration
Secondary	The percentage of patients with 10% reduction from baseline ventricular rate in the 60 minutes post drug administration.		60 minutes post drug administration
Secondary	The percentage of patients with 20% reduction from baseline ventricular rate in the 60 minutes post drug administration.		60 minutes post drug administration
Secondary	The percentage of patients cardioverting into sinus rhythm in the 60 minutes post drug administration.		60 minutes post drug administration
Secondary	Rating of Treatment Satisfaction Questionnaire for Medication (TSQM-9).		60 minutes post drug administration